Skip to main content

Table 2 Clinicopathologic features and PTHrP expression

From: Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome

  PTHrP positive PTHrP negative χ2 P value
No. (%) No. (%)
Age     
 ≤55 146 (53.9 %) 121 (53.5 %) 0.006 0.941
 >55 125 (46.1 %) 105 (46.5 %)   
Tumor size     
 ≤2 cm 133 (49.1 %) 145 (64.2 %) 11.372 0.001
 >2 cm 138 (50.9 %) 81 (35.8 %)   
Skin involvementa     
 No 223 (82.3 %) 196 (86.7 %) 1.834 0.176
 Yes 48 (17.7 %) 30 (13.3 %)   
LN metastasis     
 No 154 (57.7 %) 148 (67.6 %) 5.014 0.025
 Yes 113 (42.3 %) 71 (32.4 %)   
 Unknown 4 7   
Histologic grade     
 ≤II 187 (70.8 %) 165 (74.7 %) 0.885 0.347
 >II 77 (29.2 %) 56 (25.3 %)   
 Unknown 7 5   
Clinical stage     
 I 95 (35.1 %) 100 (44.2 %) 6.937 0.031
 II 116 (42.8 %) 94 (41.6 %)   
 III 60 (22.1 %) 32 (14.2 %)   
ER     
 (−) 78 (29.2 %) 56 (26.9 %) 0.303 0.582
 (+) 189 (70.8 %) 152 (73.1 %)   
 Unknown 4 18   
HER-2     
 (−) 98 (40.3 %) 79 (39.7 %) 0.018 0.893
 (+) 145 (59.7 %) 120 (60.3 %)   
 Unknown 28 27   
Tumor type     
 IDCb 231 (85.2 %) 192 (85.0 %) 0.008 0.929
 Non-IDCc 40 (14.8 %) 34 (15.0 %)   
TGF-β     
 (−) 116 (42.8 %) 107 (47.3 %) 1.027 0.311
 (+) 155 (57.2 %) 119 (52.7 %)   
  1. askin involvement: edema, redness, nodularity, or ulceration
  2. bIDC, invasive ductal carcinoma
  3. cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma